Stock Report

Download full stock data and analysis for free Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Anuh Pharma Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: ANUHPHR | BSE: 506260

₹83.57

up-down-arrow ₹-0.01 (-0.01%)

As on 28-Aug-2026IST

Market cap

info icon

₹840 Cr

Revenue (TTM)

info icon

₹779 Cr

P/E Ratio

info icon

19

P/B Ratio

info icon

2.3

Div. Yield

info icon

1.8 %

Edit peer-selector-edit
Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 840 35,497 29,798 16,589 15,507
Revenue (₹ Cr)
 779 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 44.17 1,018.97 497.77 603.02 270.18
Net Margin (%)
 5.62 10.47 20.72 22.63 23.29
RoE (%)
 13.01 21.30 28.49 19.61 14.45
Price to Earnings
 19.02 35.10 59.86 27.51 56.31
Price-To-Book
 2.31 6.79 14.74 4.76 7.48

Income Statement (₹ Cr)

Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
778.99 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
785.90 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
714.14 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
64.85 1,943.92 762.90 836.69 388.38
Depreciation arrow
11.30 425.10 98.11 78.88 74.78
EBIT arrow
53.55 1,518.82 664.79 757.81 313.60
Interest arrow
0.27 148.45 26.33 5.43 0.26
Other Income arrow
6.91 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
60.20 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
16.03 370.94 171.48 197.53 91.39
Profit after Tax arrow
44.17 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
352.22 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
2.14 723.57 345.47 142.73 50.51
Current Liabilities arrow
203.00 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
557.37 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
92.06 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
451.32 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
557.37 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
0.00 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
248.31 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
7.45 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-3.01 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
17.84 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
-26.33 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-11.50 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
16.02 25.25 27.50 24.61 18.04
ROE (%) arrow
13.01 21.30 28.49 19.61 14.45
ROA (%) arrow
8.30 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
6.87 15.68 28.03 29.25 28.29
Net Margin (%) arrow
5.62 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
9.70 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
4.48 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
-4.28 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-52.14 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
8.04 11.36 22.95 18.43 11.27

Valuation Ratios

 Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
19.02 34.38 59.86 26.64 55.82
Price / Book Value arrow
2.31 6.79 14.74 4.76 7.48
Dividend Yield (%) arrow
1.79 0.19 0.15 0.37 0.51
EV/EBITDA arrow
12.13 18.80 38.85 18.89 38.86
Market Cap (₹ Cr) arrow
672.73 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-- 0.16 -- -- --
Current Ratio arrow
2.22 1.43 2.09 5.21 7.39
Quick Ratio arrow
1.50 0.82 1.37 3.85 5.46
Interest Coverage arrow
228.16 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Anuh Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
30.63 26.46 22.82 41.42 41.52
Asset Turnover arrow
1.46 1.09 0.93 0.70 0.52
Receivable days arrow
106.48 88.68 77.32 144.58 169.86
Inventory Days arrow
52.06 84.11 80.83 96.67 97.92
Payable days arrow
105.46 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
53.08 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...